Verubecestat, a BACE1 inhibitor, was once considered a promising AD drug as it was found to reduce Aβ levels in the cerebrospinal fluid of rats, monkeys and AD patients in a preliminary study [35]. This evidence concerns the gene BACE1 and Alzheimer disease.